The role of long noncoding RNA SNHG7 in human cancers (Review).
Abstract Long non-coding RNAs (lncRNAs) have been demonstrated to serve important roles in a variety of human tumor types. The lncRNA small nucleolar RNA host gene 7 (SNHG7) is associated with a variety of cancer types, such as esophageal cancer, breast cancer and gastric neoplasia. Based on previous studies that examined SNHG7 expression in tumors, it has become clear that SNHG7 modulates tumorigenesis and cancer progression by acting as a competing endogenous RNA. SNHG7 can sponge tumor-suppressive microRNAs and regulate downstream signaling pathways. In addition, overexpression of SNHG7 is associated with the c...
Source: Clinical Breast Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Bian Z, Ji W, Xu B, Huang W, Jiao J, Shao J, Zhang X Tags: Mol Clin Oncol Source Type: research

Risk factors of breast intraductal lesions in patients without pathological nipple discharge.
Abstract The majority of breast cancer arises from the ductal epithelium. It is crucial in the diagnosis and treatment of breast cancer by detecting intraductal lesions at an early stage. The typical clinical characteristic of intraductal lesions is pathological nipple discharge (PND), although many patients with intraductal lesions do not exhibit PND. It is a serious challenge for clinicians to detect patients with intraductal lesions without PND at an early stage. The aim of the present study was to investigate the risk factors associated with intraductal lesions in patients without PND. This retrospective datab...
Source: Clinical Breast Cancer - August 26, 2020 Category: Cancer & Oncology Authors: Shen L, Ye Y, Liu X, Li W, Wei J, Ke Z, Yang S, Yang Z Tags: Mol Clin Oncol Source Type: research

Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
CONCLUSION: GGO-featured lung adenocarcinoma has no response to chemotherapy. For these patients, chemotherapy should not be a treatment option. PMID: 32356178 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Zhang Y, Deng C, Ma X, Gao Z, Wang S, Zheng Q, Xia G, Wen Z, Han H, Fu F, Liu Q, Hu H, Li Y, Wong KK, Chen H Tags: J Cancer Res Clin Oncol Source Type: research

Historical retrospective of the SRC oncogene and new perspectives (Review).
Abstract Since its first discovery as part of the Rous sarcoma virus (RSV) genome, the c-SRC (SRC) proto-oncogene has been proved a key regulator of cancer development and progression, and thus it has been highlighted as an attractive target for anti-cancer therapeutic strategies. Though the exact mechanisms of its action are still not fully understood, SRC protein mediates crucial normal cell functions, such as cell development, proliferation and survival, and its dysregulation is considered as an oncogenic signature and a driving force for cancer initiation. In the present review, we present a flashback to the h...
Source: Clinical Breast Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Simatou A, Simatos G, Goulielmaki M, Spandidos DA, Baliou S, Zoumpourlis V Tags: Mol Clin Oncol Source Type: research

Molecular analysis of circulating tumor DNA from breast cancer patients before and after surgery and following adjuvant chemotherapy.
Abstract The primary aim of the present study is to provide a complex molecular profile of tumors using liquid biopsy and to monitor profile changes over time in association with surgery and administered adjuvant therapy. Our secondary aim was to compare the liquid biopsy profile with the tissue biopsy and assess concordance. A total of 27 samples of circulating tumor DNA (ctDNA) collected from 9 breast cancer patients at three different time points and their matched formalin-fixed and paraffin-embedded (FFPE) samples of primary tumor were analyzed with targeted next-generation sequencing. Somatic pathogenic varia...
Source: Clinical Breast Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Zelinova K, Jagelkova M, Laucekova Z, Bobrovska M, Dankova Z, Grendar M, Dokus K Tags: Mol Clin Oncol Source Type: research

Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer.
a ENS Abstract The early detection of breast cancer enables the use of less aggressive treatment and increases patient survival. The transmembrane glycoprotein mucin 1, which is also known as cancer antigen 15-3 (CA15-3), is aberrantly glycosylated and overexpressed in a variety of epithelial cancers, and serves a crucial role in the progression of the disease. CA15-3 is currently used as a marker of breast cancer. In the present study, CA15-3 concentrations in saliva and blood of patients with breast cancer were evaluated to test new assays to detect salivary CA15-3 in addition to ELISA and its diagnostic value. ...
Source: Clinical Breast Cancer - July 29, 2020 Category: Cancer & Oncology Authors: Assad DX, Mascarenhas ECP, Normando AGC, Chardin H, Barra GB, Pratesi R, Nóbrega YKM, Acevedo AC, Guerra ENS Tags: Mol Clin Oncol Source Type: research

Predicting therapeutic efficacy of endocrine therapy for stage IV breast cancer by tumor-infiltrating lymphocytes.
Abstract The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. These immune responses may be evaluated by measuring tumor-infiltrating lymphocytes (TILs), which has been frequently verified clinically. In the present study, the prediction of the therapeutic effect of endocrine therapy by TILs on stage IV breast cancer was clinically analyzed. Data from 40 patients who underwent endocrine therapy as the initial drug therapy for stage IV breast cancer were used. The correlation between TILs, evaluated according to standard...
Source: Clinical Breast Cancer - July 29, 2020 Category: Cancer & Oncology Authors: Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Shibutani M, Amano R, Takashima T, Tomita S, Hirakawa K, Ohira M Tags: Mol Clin Oncol Source Type: research

Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).
Abstract Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies. PMID: 32715108 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 29, 2020 Category: Cancer & Oncology Authors: Corbin KS, Breen WG, Strauss JB Tags: Clin Transl Radiat Oncol Source Type: research

Hot Flashes: Clinical Summary of the ONS Guidelines ™ for Cancer Treatment-Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer.
Hot Flashes: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer. Clin J Oncol Nurs. 2020 Aug 01;24(4):430-433 Authors: Kaplan M, Mahon SM, Lubejko BG, Ginex PK Abstract Cancer-related hot flashes are often a lasting and distressing side effect of hormone-blocking therapies that are most often experienced by women with breast cancer and men with prostate cancer treated with these therapies. Hot flashes have been defined as a sensation of heat that may be accompanied by facial flushing, perspiration, chills, hea...
Source: Clinical Breast Cancer - July 19, 2020 Category: Cancer & Oncology Authors: Kaplan M, Mahon SM, Lubejko BG, Ginex PK Tags: Clin J Oncol Nurs Source Type: research

Postdiagnosis Physical Activity: Association With Long-Term Fatigue and Sleep Disturbance in Older Adult Breast Cancer Survivors.
This article aimed to examine if postdiagnosis physical activity is associated with lower long-term fatigue and sleep disturbance in older adult breast cancer survivors. METHODS: Data were analyzed of a prospective cohort of 440 breast cancer survivors aged 65 years or older from the Women's Health Initiative study. Multiple linear and logistic regression models were used to examine associations of physical activity with fatigue and sleep disturbance. FINDINGS: Higher postdiagnosis physical activity was associated with lower long-term fatigue but was not associated with lower sleep disturbance after adjusting for...
Source: Clinical Breast Cancer - July 19, 2020 Category: Cancer & Oncology Authors: Vasbinder A, Reding KW, Wang D, Han CJ, Zaslavsky O, Langford D, Cespedes Feliciano EM, Barrington WE, Paskett ED Tags: Clin J Oncol Nurs Source Type: research

Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?
CONCLUSION: None of the six proteins proved to be suitable prognostic factors for OS and DSF in patients with TNBC. PMID: 32266539 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 14, 2020 Category: Cancer & Oncology Authors: Schmidt G, Solomayer EF, Bohle RM, Gerlinger C, Radosa JC, Endrikat J, Kasoha M Tags: J Cancer Res Clin Oncol Source Type: research

Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
CONCLUSIONS: HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2+/EGFR+/CD19- tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells. PMID: 32449004 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 14, 2020 Category: Cancer & Oncology Authors: Thakur A, Scholler J, Schalk DL, June CH, Lum LG Tags: J Cancer Res Clin Oncol Source Type: research

Cancer risks in patients with vitiligo: a Mendelian randomization study.
Abstract PURPOSE: Few studies have investigated the relationship between vitiligo and risks of various types of cancers, especially those other than skin cancer. Conventional observational studies are susceptible to potential confounders and inverse causation. With a Mendelian randomization approach, we were able to evaluate the causality between vitiligo and different cancer risks. METHODS: 37 vitiligo-related single-nucleotide polymorphisms identified by the published genome-wide association studies were used as instrumental variables in our study. Summary data of individual-level genetic information were o...
Source: Clinical Breast Cancer - July 14, 2020 Category: Cancer & Oncology Authors: Wen Y, Wu X, Peng H, Li C, Jiang Y, Liang H, Zhong R, Liu J, He J, Liang W Tags: J Cancer Res Clin Oncol Source Type: research

Breast cancer: are long-term and intermittent endocrine therapies equally effective?
CONCLUSION: Knowledge of initiation and growth of tumors with known effects of neo-ATs suggest that intermittent endocrine ATs may achieve the same results as EATs but with improved quality of life and survival because of fewer side effects and better compliance. The challenge for developments of repeated ATs becomes: how short is short enough. PMID: 32472445 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 14, 2020 Category: Cancer & Oncology Authors: Engel J, Schubert-Fritschle G, Emeny R, Hölzel D Tags: J Cancer Res Clin Oncol Source Type: research

Cancer and Systemic Lupus Erythematosus.
Abstract Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. A decreased risk of breast, ovarian, and endometrial cancer might be driven by hormonal factors or lupus-related antibodies, but these link...
Source: Clinical Breast Cancer - July 9, 2020 Category: Cancer & Oncology Authors: Ladouceur A, Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, Gordon C, Hansen JE, Bernatsky S Tags: Rheum Dis Clin North Am Source Type: research

Risk Factors and Cancer Screening in Myositis.
Abstract The idiopathic inflammatory myopathies, particularly dermatomyositis, are associated with an increased risk of cancer. Lung, ovarian, breast, colon, prostate, and cervical cancers, and hematologic malignancies, are among the most common associated cancers. Risk stratification for cancer in patients with myositis is based on clinical risk factors/red flags, myositis clinical subtypes, and myositis-specific autoantibodies. Clinical risk factors include older age at disease onset, male gender, dysphagia, acute onset/refractory myositis, cutaneous ulceration, necrosis/vasculitis, and elevated inflammatory mar...
Source: Clinical Breast Cancer - July 9, 2020 Category: Cancer & Oncology Authors: Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R Tags: Rheum Dis Clin North Am Source Type: research

Myxofibrosarcoma that Developed Rapidly in the Breast of an Elderly Man and Recurred Early after Surgery: A Case Report.
CONCLUSIONS: It is important to consult a soft tissue oncologist for tumors in the breast and perform appropriate examination and treatment if soft tissue tumors cannot be ruled out. PMID: 32602101 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Tsuda B, Ogura G, Kumaki N, Sakaeda S, Ishida R, Mizuno M, Yokoyama K, Terao M, Morioka T, Okamura T, Imagawa K, Kohno M, Watanabe T, Niikura N Tags: Tokai J Exp Clin Med Source Type: research

Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.
CONCLUSIONS: We suggest adding p16, p53 and HPV status to routine hystopathological examination of vulvar biopsies or surgical specimens. Predictive biomarkers for anti-EGFR and anti-PD-1/PD-L1 drugs are needed. Enough preclinical data supporting anti-angiogenic target therapies in clinical trials are existing. Hormonal receptor expression deserves further investigation. PMID: 32335720 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Giulia Mantovani, Fragomeni SM, Inzani F, Fagotti A, Della Corte L, Gentileschi S, Tagliaferri L, Zannoni GF, Scambia G, Garganese G Tags: J Cancer Res Clin Oncol Source Type: research

Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.
CONCLUSIONS: Expression of MBR in cancer cells induces apoptotic cell death with enhanced chemo-sensitization requiring the BH3L domain of MOAP-1. In animal model, the expression of MBR significantly reduces the growth of tumors, suggesting that MBR is a potent apoptotic sensitizer with potential therapeutic benefits for cancer treatment. PMID: 32377840 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Lee YH, Pang SW, Revai Lechtich E, Shah K, Simon SE, Ponnusamy S, Narayanan R, Poh CL, Tan KO Tags: J Cancer Res Clin Oncol Source Type: research

Prepectoral Dual-Port Tissue Expander Placement: Can This Eliminate Suction Drain Use?
CONCLUSIONS: Immediate breast reconstruction using a dual-chamber tissue expander offers a drain-free alternative to the immediate implant-based breast reconstruction. Our infection rate with 7.8% is lower than our own reported rates with subpectoral tissue expander reconstruction using either acellular dermal matrix or poly-4-hydroxybutyrate (17% and 11%). The overall complication rate is similar to historic data associated with breast reconstruction after mastectomy and suggests that dual-chamber expander placement offers a safe alternative possibly decreasing the patient's postoperative pain and discomfort that often is...
Source: Clinical Breast Cancer - June 13, 2020 Category: Cancer & Oncology Authors: Franck P, Chadab T, Poveromo L, Ellison A, Simmons R, Otterburn DM Tags: Ann Plast Surg Source Type: research

Utility of regional nodal irradiation in Japanese patients with breast cancer with 1-3 positive nodes after breast-conserving surgery and axillary lymph-node dissection.
Abstract The utility of regional nodal irradiation (RNI) is being considered in cases of 1-3 axillary node metastases after breast-conserving surgery (BCS) with axillary lymph-node dissection (ALND). Therefore, we examined the necessity of RNI by examining the sites of recurrences in cases at our institution. We retrospectively analyzed 5,164 cases of primary breast cancer between January 2000 and December 2014 at the Aichi Cancer Centre, identifying local and distant recurrences in 152 patients with primary breast cancer treated with BCS and ALND and who had 1-3 positive axillary nodes. All patients received whol...
Source: Clinical Breast Cancer - June 7, 2020 Category: Cancer & Oncology Authors: Gondo N, Sawaki M, Hattori M, Yoshimura A, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Ozaki Y, Endo Y, Iwata H Tags: Mol Clin Oncol Source Type: research

Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study.
Abstract Two single nucleotide polymorphisms (SNPs) of matrix metalloproteinase (MMPs) 3 and 9 are functionally implicated in the progression of various types of cancer, including breast cancer (BC). However, the roles of these SNPs remain controversial. In addition, they also vary between one population and another. Therefore, the present study aimed to investigate the possible association between MMP3-1171 5A/6A and MMP9-1562 CT SNPs and the risk of BC among Egyptians, and to elucidate the alteration of MMP3 and MMP9 gene expression in patients with BC. The present case-control study enrolled 162 patients with B...
Source: Clinical Breast Cancer - May 28, 2020 Category: Cancer & Oncology Authors: Abd Elmaogoud Ragab Ibrahim F, Essam Elfeky S, Haroun M, Abd Elrahman Ahmed M, Elnaggar M, Abd Elfatah Ismail N, Ahmed Abd El Moneim N Tags: Mol Clin Oncol Source Type: research

Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS.
In conclusion, preoperatively diagnosed non-mass-type DCIS represented an underestimation in approximately 27% of cases. In particular, the presence of a clinically abnormal palpation increases the chance of upstaging to invasive cancer. PMID: 32454975 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 28, 2020 Category: Cancer & Oncology Authors: Oda G, Nakagawa T, Ogawa A, Kumaki Y, Hosoya T, Sugimoto H, Ishiba T, Mio M, Fujioka T, Kubota K, Onishi I, Uetake H Tags: Mol Clin Oncol Source Type: research

Taste Disorders: Effect of Education in Patients With Breast Cancer Receiving Chemotherapy.
This study evaluated the effects of taste disorder-related education on meal satisfaction and sense of taste in Japanese women with breast cancer undergoing chemotherapy. METHODS: A sample of 53 newly diagnosed women with breast cancer scheduled for chemotherapy treatment were randomly assigned to the control or intervention (nurse-provided education about chemotherapy-associated taste disorders) group. Meal satisfaction and sense of taste were assessed using a visual analog scale. FINDINGS: The proportions of patients with meal dissatisfaction and impaired sense of taste were lower in the intervention group than...
Source: Clinical Breast Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Asano S, Sawatari H, Mentani H, Shimada Y, Takahashi M, Fudano K, Sasaki K, Niitani M, Tanabe K, Kataoka T Tags: Clin J Oncol Nurs Source Type: research

Cutaneous Metastases: A Case Study on Clinical Care for Patients.
Abstract Cutaneous metastases (CMs) signal the spread of a primary tumor to the skin and dermis, particularly in patients with melanoma or with breast, lung, or gastrointestinal cancers. Although these lesions may present as superficial and painless, some CMs may lead to ulceration, drainage, and discomfort, causing distress to patients. Oncology nurses require knowledge about the clinical presentation of CMs, including incidence, pathophysiology, diagnostic evaluation, and complex symptomatology, as well as standard treatment and care for patients. In addition, nurses can provide psychosocial interventions to ass...
Source: Clinical Breast Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Padden SM, Abraham EJ, Viscosi E, Habin KR, Lundquist DM Tags: Clin J Oncol Nurs Source Type: research

Breast Cancer Survivor Symptoms: A Comparison of Physicians' Consultation Records and Nurse-Led Survivorship Care Plans.
Abstract BACKGROUND: Survivorship care plans (SCPs) have been used to address ongoing health problems associated with the diagnosis and treatment of early-stage breast cancer. OBJECTIVES: The aim of this article was to determine whether nurse-led consultations using SCPs, as compared with a standard medical consultation, identify more side effects and supportive care needs and lead to appropriate referral patterns. METHODS: The study audited 160 retrospective medical clinic and nursing SCP records in a sample of patients receiving treatment for early-stage breast cancer at a tertiary-level breast service...
Source: Clinical Breast Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Kozul C, Stafford L, Little R, Bousman C, Park A, Shanahan K, Mann GB Tags: Clin J Oncol Nurs Source Type: research

Wellness Coaching: An Intervention to Increase Healthy Behavior in Breast Cancer Survivors.
This study assessed the feasibility and effectiveness of WCIs for increasing physical activity in breast cancer survivors; secondary measures included changes in dietary habits, weight, and QOL. METHODS: 20 obese or overweight breast cancer survivors who recently completed active breast cancer treatment were recruited into a single-arm, 12-week WCI pilot feasibility study. The intervention was comprised of one in-person wellness coaching visit followed by four telephone calls over 12 weeks and 12 weekly emails containing wellness recommendations. FINDINGS: Significant improvements from pre- to postintervention we...
Source: Clinical Breast Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Stan DL, Cutshall SM, Adams TF, Ghosh K, Clark MM, Wieneke KC, Kebede EB, Donelan Dunlap BJ, Ruddy KJ, Hazelton JK, Butts AM, Jenkins SM, Croghan IT, Bauer BA Tags: Clin J Oncol Nurs Source Type: research

Expression of androgen receptor and its regulatory molecule Lin28 in non-luminal subtype breast cancer.
In conclusion, Lin28 may be a novel marker for prognosis and targeted for treatment in HER2 subtype breast cancer. PMID: 32382417 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 10, 2020 Category: Cancer & Oncology Authors: Sa-Nguanraksa D, Pongthong W, Samarnthai N, Mitpakdi K, Chuangsuwanich T, Limjindaporn T, Kulprom A, O-Charoenrat P Tags: Mol Clin Oncol Source Type: research

Dosimetric comparison of incidental axillary irradiation between three-dimensional conformal and volumetric modulated arc techniques for breast cancer.
In conclusion, VMAT decreased incidental axillary irradiation, even in the absence of a dose-volume constraint on the axilla, and can, therefore, decrease the risk of radiotherapy-related lymphedema. However, caution is also required because it is unclear whether this incidental axillary irradiation is beneficial for reducing recurrence on the axilla. PMID: 32337037 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Jo IY, Kim ES, Kim WC, Min CK, Yeo SG Tags: Mol Clin Oncol Source Type: research

Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.
Abstract Circulating tumor cells (CTCs) play a pivotal role in tumor dissemination and progression, and are considered to be a critical part of the metastatic cascade. The aim of the present research article was to examine breast cancer-specific mutations in primary breast cancer (PBC) using targeted resequencing. A total of 78 patients with PBC were enrolled into this translational study. Reverse transcription-quantitative PCR assay for the expression of epithelial markers (CK19) or epithelial-to-mesenchymal transition (EMT)-related genes (TWIST1, SNAIL1, SLUG and ZEB1) was applied for identification of CTCs prio...
Source: Clinical Breast Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Mego M, Karaba M, Sedlackova T, Benca J, Repiska G, Krasnicanova L, Macuch J, Sieberova G, Jurisova S, Pindak D, Kalavska K, Mardiak J, Minarik G Tags: Mol Clin Oncol Source Type: research

Correlation of sex-determining region Y-box 30 with tumor characteristics and its prognostic value in breast cancer.
Abstract OBJECTIVE: Sex-determining region Y-box 30 (SOX30) suppresses progression of several cancers, whereas its role in breast cancer is unclear. Therefore, we aimed to determine the correlation of SOX30 with tumor characteristics and prognosis in breast cancer patients. METHODS: The tumor samples of 510 breast cancer patients who underwent resection were obtained, and SOX30 expression was analyzed by immunohistochemistry. Clinical characteristics, disease-free survival (DFS), and overall survival (OS) of breast cancer patients were recorded. RESULTS: There were 368 breast cancer patients in SOX30 low...
Source: Clinical Breast Cancer - March 10, 2020 Category: Cancer & Oncology Authors: Peng H, Luo Y, Wu J, Yin W Tags: J Clin Lab Anal Source Type: research

Exploiting the folate receptor α in oncology.
Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020 Mar 09;: Authors: Scaranti M, Cojocaru E, Banerjee S, Banerji U Abstract Folate receptor α (FRα) came into focus as an anticancer target many decades after the successful development of drugs targeting intracellular folate metabolism, such as methotrexate and pemetrexed. Binding to FRα is one of several methods by which folate is taken up by cells; however, this receptor is an attractive anticancer drug target owing to the overexpression of FRα in a range of solid tumours, including ovarian, lung and b...
Source: Clinical Breast Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Scaranti M, Cojocaru E, Banerjee S, Banerji U Tags: Nat Rev Clin Oncol Source Type: research

Adjuvant and neoadjuvant therapy for breast cancer.
Abstract Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer histological types. Systemic therapy is selected according to recurrence risk, with the treatment for low-risk patients being de-escalated, while high-risk patients receive aggressive systemic treatment with an adequate dose and duration. Neoadjuvant systemic therapy has a different aim. The efficacy of systemic therapies, based on the sensitivities to drugs...
Source: Clinical Breast Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Shien T, Iwata H Tags: Jpn J Clin Oncol Source Type: research

Could the Women's Health Initiative Breathe New Life Into Breast Cancer Prevention?
PMID: 32150487 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Ligibel JA Tags: J Clin Oncol Source Type: research

Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
This study aimed to clarify treatment patterns in elderly patients with recurrent ovarian cancer. PATIENTS AND METHODS: We used an ovarian cancer database containing the diagnosis and initial therapy of all patients at the National Cancer Center Hospital in Japan from 2007 to 2014. Patients were stratified into the platinum-sensitive group and the platinum-resistant group. We retrospectively assessed chemotherapy use in patients aged ≤ 64, 65-69, 70-74, 75-79, and ≥ 80 years. RESULTS: Among 253 patients (sensitive group: 135; resistant group: 118), by age group 91%, 95%, 100...
Source: Clinical Breast Cancer - March 6, 2020 Category: Cancer & Oncology Authors: Kato MK, Yunokawa M, Bun S, Shimoi T, Yonemori K, Miyasaka N, Kato T, Tamura K Tags: J Cancer Res Clin Oncol Source Type: research

Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study.
CONCLUSION: Guideline adherence is suboptimal. Although survivor SCP possession is associated with better adherence, few survivors and PCPs have one. New strategies to improve adherence are needed. PMID: 32142393 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2020 Category: Cancer & Oncology Authors: Yan AP, Chen Y, Henderson TO, Oeffinger KC, Hudson MM, Gibson TM, Neglia JP, Leisenring WM, Ness KK, Ford JS, Robison LL, Armstrong GT, Yasui Y, Nathan PC Tags: J Clin Oncol Source Type: research

Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
PMID: 32142394 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2020 Category: Cancer & Oncology Authors: Ganz PA, Van Dyk K Tags: J Clin Oncol Source Type: research

National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015.
CONCLUSIONS: We estimated the incidence rate of thymic carcinoma in Japan based on the designated cancer care hospital-based cancer registry. The half of all patients with thymic carcinoma was unfit for multimodality therapy, including thoracic surgery. PMID: 32134448 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Koizumi T, Otsuki K, Tanaka Y, Noguchi T, Fukushuima T, Kobayashi T, Ozawa T, Sekiguchi N, Hamanaka K Tags: Jpn J Clin Oncol Source Type: research

Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers.
Abstract The promising expectations about personalized medicine have opened the path to routine large-scale sequencing and increased the importance of genetic counseling for hereditary cancers, among which hereditary breast and ovary cancers (HBOC) have a major impact. High-throughput sequencing, or Next-Generation Sequencing (NGS), has improved cancer patient management, ameliorating diagnosis and treatment decisions. In addition to its undeniable clinical utility, NGS is also unveiling a large number of variants that we are still not able to clearly define and classify, the variants of uncertain significance (VU...
Source: Clinical Breast Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Federici G, Soddu S Tags: J Exp Clin Cancer Res Source Type: research

PIK3C δ expression by fibroblasts promotes triple-negative breast cancer progression.
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression. J Clin Invest. 2020 Mar 03;: Authors: Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, Ntafis V, Huang P, Ditsiou A, Vella V, Yadav K, Bienkowska K, Bresciani G, Kang K, Li L, Carter P, Benstead-Hume G, O'Hanlon T, Dean M, Pearl FM, Lee SC, Rakha EA, Green AR, Kontoyiannis DL, Song E, Stebbing J, Giamas G Abstract As there is growing evidence for the tumor microenvironment's (TME) role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple negative breast cancer (TNBC). Usi...
Source: Clinical Breast Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, Ntafis V, Huang P, Ditsiou A, Vella V, Yadav K, Bienkowska K, Bresciani G, Kang K, Li L, Carter P, Benstead-Hume G, O'Hanlon T, Dean M, Pearl FM, Lee SC, Rakha EA, Green AR, Kontoyiannis DL, Song E Tags: J Clin Invest Source Type: research

MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer.
CONCLUSION: In summary, all the results demonstrate that miR-124-3p.1 promotes TNBC cell growth by controlling Axin1, suggesting that targeting miR-124-3p.1 might offer an effective therapeutic strategy for TNBC in the future. PMID: 32125723 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Yang W, Cui G, Ding M, Yang M, Dai D Tags: J Clin Lab Anal Source Type: research

Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Abstract PURPOSE: Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied. This trial explored the feasibility of a short-term course of letrozole and sought to determine whether treatment results in measurable radiographic and biologic changes in estrogen receptor (ER)-positive DCIS. PATIENTS AND METHODS: A phase II single-arm multicenter cooperative-group trial was conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion. Patients were treated with letrozole 2.5 mg per day for 6 months before surgery. Breast magne...
Source: Clinical Breast Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N Tags: J Clin Oncol Source Type: research

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
CONCLUSION: A substantial proportion of women with breast cancer carrying germline pathogenic variants in predisposition genes do not qualify for testing by NCCN criteria. Expansion of NCCN criteria to include all women diagnosed at ≤ 65 years of age improves the sensitivity of the selection criteria without requiring testing of all women with breast cancer. PMID: 32125938 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, Sandhu N, Rhodes DJ, Klassen C, Peethambaram PP, Haddad TC, Olson JE, Hoskin TL, Goetz MP, Domchek SM, Bo Tags: J Clin Oncol Source Type: research

De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
PMID: 32125939 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Lazzeroni M, DeCensi A Tags: J Clin Oncol Source Type: research

Breast cancer: an update on treatment-related infertility.
Abstract Breast cancer (BC) is the most common malignancy in women with a significant increasing incidence during the reproductive life. However, based on the newest anti-cancer molecular targeting drugs, successful treatments lead to the disease healing particularly in young patients, thus refreshing their motherhood programs. However, as effect of the BC treatment, a premature depletion of the ovarian follicle reserve occurs in more than one-third of patients resulting in permanent infertility. To prevent the cancer treatment-related infertility (CTRI), several options are today utilized. Besides the ovary suppr...
Source: Clinical Breast Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Silvestris E, Dellino M, Cafforio P, Paradiso AV, Cormio G, D'Oronzo S Tags: J Cancer Res Clin Oncol Source Type: research

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
CONCLUSIONS: The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20-25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this...
Source: Clinical Breast Cancer - March 1, 2020 Category: Cancer & Oncology Authors: MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG Tags: J Cancer Res Clin Oncol Source Type: research

Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine.
Abstract Radiation therapy is a standard therapeutic option in the post-operative setting for early breast cancer patients after breast conserving surgery, providing a substantial benefit in reducing the risk of local relapse with a consequent survival gain. Nevertheless, the reduction in the burden related to treatment is becoming crucial in modern oncology for both local and systemic therapies and investigational efforts are being put forward by radiations oncologists to identify a subset of women at very low risk to be potentially omitted from post-operative irradiation after breast conservation. Clinical facto...
Source: Clinical Breast Cancer - February 25, 2020 Category: Cancer & Oncology Authors: Franco P, De Rose F, De Santis MC, Pasinetti N, Lancellotta V, Meduri B, Meattini I, Clinical Oncology Breast Cancer Group (COBCG) Investigators Tags: Clin Transl Radiat Oncol Source Type: research

DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.
Conclusion: Kinetic parameters measured 2.5 weeks post-SABR in both single fraction and three fraction groups were indicative of response but only the single fraction protocol led to enhancement in the surrounding tissue. Our results also suggest that DCE-MRI one-week post-SABR may be too early for response assessment, at least for single fraction SABR, whereas 2.5 weeks appears sufficiently long to minimize confounding acute effects. PMID: 32021911 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 7, 2020 Category: Cancer & Oncology Authors: Mouawad M, Biernaski H, Brackstone M, Lock M, Yaremko B, Shmuilovich O, Kornecki A, Ben Nachum I, Muscedere G, Lynn K, Prato FS, Thompson RT, Gaede S, Gelman N Tags: Clin Transl Radiat Oncol Source Type: research

Efficient dose-finding for drug combination studies involving a shift in study populations.
We describe the adaptation of a model-based design for identifying the maximum tolerated dose combination that efficiently moves from the initial phase in an advanced disease population to the second phase in the target population. Operating characteristics demonstrate the ability of the method to accurately predict true maximum tolerated dose combinations in a high percentage of trials with reasonable sample sizes, while treating participants at and around desirable combinations. The proposed design is a practical, early-phase, adaptive method for use with drug combination dose finding in the presence of shifting patient ...
Source: Clinical Breast Cancer - January 17, 2020 Category: Cancer & Oncology Authors: Wages NA, Millard TA, Dillon PM, Brenin CM, Petroni GR Tags: Contemp Clin Trials Commun Source Type: research

NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.
Abstract Sentinel lymph node biopsy alone, without complete axillary lymph node dissection, is the standard treatment of the axilla nodal chain in early-stage breast cancer patients presenting a negative sentinel lymph node. The updated results of the IBCSG 23-01 randomized trial recently provided evidence that this approach could be extended to early-stage breast cancer patients presenting only micrometastasis in the sentinel lymph node. On the other hand, patients with large operable or locally advanced breast cancer and clinically positive lymph nodes currently receive neoadjuvant chemotherapy and sentinel lymp...
Source: Clinical Breast Cancer - December 26, 2019 Category: Cancer & Oncology Authors: Tinterri C, Canavese G, Bruzzi P, Dozin B Tags: Contemp Clin Trials Commun Source Type: research